ReviewBest practice & research. Clinical rheumatology2008
Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations.
Review in Best practice & research. Clinical rheumatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 218 citations in OpenAlex.
- Clinical and Genetic Profile of Chinese Familial Hypocalciuric Hypercalcemia Type 1 (FHH1): A Retrospective Study.Endocrine · 2026Article
- A novel homozygous inactivating mutation of the calcium-sensing receptor causing familial hypocalciuric hypercalcemia complicated with primary hyperparathyroidism due to parathyroid adenoma: A case report.The Journal of international medical research · 2026Article
- Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations.Journal of endocrinological investigation · 2025Review
- Vitamin D Deficiency in Chronic Childhood Disorders: Importance of Screening and Prevention.Nutrients · 2023Review
- Temperature sensing by the calcium-sensing receptor.Frontiers in physiology · 2023Article
- Dent-2 disease with a Bartter-like phenotype caused by the Asp631Glu mutation in the OCRL gene.BMC nephrology · 2022Article
- Recurrent hypocalcemic tetany presenting to the emergency room: Answers.Pediatric nephrology (Berlin, Germany) · 2022Article
- Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases.Frontiers in endocrinology · 2022Review
- Renal cell markers: lighthouses for managing renal diseases.American journal of physiology. Renal physiology · 2021Article
- The role of calcium-sensing receptor signaling in regulating transepithelial calcium transport.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Structural mechanism of cooperative activation of the human calcium-sensing receptor by CaCell research · 2021Article
- Rare diseases caused by abnormal calcium sensing and signalling.Endocrine · 2021Review
- Endocrine Diseases of Newborn: Epidemiology, Pathogenesis, Therapeutic Options, and Outcome "Current Insights Into Disorders of Calcium and Phosphate in the Newborn".Frontiers in pediatrics · 2021Review
- Case Report: Unusual Presentations of Loss-of-Function Mutations of the Calcium-Sensing Receptor.Frontiers in medicine · 2021Article
- A clinical perspective of parathyroid hormone related hypercalcaemia.Reviews in endocrine & metabolic disorders · 2020Review
- Clinical and Biochemical Features in a Case of Familial Hypocalciuric Hypercalcemia Type 3 withCase reports in pediatrics · 2020Article
- [Prolonged continuous infusion of teriparatide promotes bone metabolism in normal but not in castrated mice].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2019Article
- Review
- Case report: acute clinical presentation and neonatal management of primary hyperparathyroidism due to a novel CaSR mutation.BMC pediatrics · 2018Article
- Incidence of hypocalcemia and hypercalcemia in hospitalized patients: Is it changing?Journal of clinical & translational endocrinology · 2018Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The extracellular calcium (Ca2+o)-sensing receptor (CaSR) enables the parathyroid glands and other CaSR-expressing cells involved in calcium homeostasis, such as the kidney and bone, to sense alterations in the level of Ca2+o and to respond with changes in function that are directed at normalizing the blood calcium concentration. Several disorders of Ca2+o sensing arise from inherited or acquired abnormalities that 'reset' the serum calcium concentration upwards or downwards. Heterozygous inactivating mutations of the CaSR produce a benign form of hypercalcaemia, termed 'familial hypocalciuric hypercalcaemia', while homozygous mutations produce a much more severe hypercalcaemic disorder resulting from marked hyperparathyroidism, called 'neonatal severe hyperparathyroidism'. Activating mutations cause a hypocalcaemic syndrome of varying severity, termed 'autosomal-dominant hypocalcaemia or hypoparathyroidism' as well as Bartter's syndrome type V. Calcimimetic CaSR activators and calcilytic CaSR antagonists have also been developed with potential for use in the treatment of these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.